How Cell-Free DNA Synthesis is Revolutionising Biotechnology

The DNA Manufacturing Bottleneck No One Talks About

While Watson and Crick’s 1953 discovery unlocked the structure of DNA, a critical problem has plagued biotechnology for decades: producing DNA is painfully slow, expensive, and limited.

Traditional plasmid DNA manufacturing can take months to over a year. For researchers developing gene therapies, mRNA vaccines, or diagnostic tools, this timeline isn’t just inconvenient, it’s a fundamental barrier to innovation.

But a breakthrough from Newcastle University is changing everything. NunaBio’s NB-3 platform can produce 40mg of linear DNA in just 80 minutes per batch, with gram-scale production achievable within seven days. This cell-free enzymatic approach eliminates bacterial endotoxins, plasmid limitations, and the complex purification challenges that have defined DNA production for 40 years.

The Forgotten Pioneers Who Built the Foundation

The story of DNA didn’t begin in 1953. It began in 1869, when Swiss chemist Friedrich Miescher isolated a mysterious phosphorus-rich substance from white blood cells, extracted from pus-soaked surgical bandages. He called it “nuclein” and predicted it belonged to an entirely new class of biological molecules.[3,4] He was right.

Decades later, Phoebus Levene decoded the chemical structure of nucleotides, identifying the phosphate-sugar-base arrangement that makes up both RNA and DNA.[2] The breakthrough that connected chemistry to structure came from Edwin Chargaff, who discovered that the amount of adenine approximately equals thymine, and guanine approximately equals cytosine. These ratios became the key to unlocking DNA’s double helix structure.[2]

Watson and Crick’s early models were wrong, they had bases pointing outward like cactus spines. The turning point came when Jerry Donohue corrected the atomic configurations of thymine and guanine. With revised cardboard cutouts, the base pairs suddenly fitted together perfectly, held by hydrogen bonds that satisfied Chargaff’s rules.[2]

The lesson? Science rarely moves in straight lines. Progress comes from accumulated insights, corrections, and sometimes, extraordinary luck, as Professor Matthew Cobb notes in his biography of Francis Crick.[5]

The Plasmid Problem: Why Traditional DNA Manufacturing is a Bottleneck

The global DNA synthesis market is forecast to reach £3.4bn by 2025, with demand reaching hundreds of kilograms, vastly outstripping current supply capacity.

Traditional plasmid DNA production follows a multi-step process: E. coli bacteria are engineered to carry the desired plasmid, cultured with antibiotic selection, harvested, lysed with alkaline solutions, and purified through complex chromatography.[7] The timeline? Months to over a year from order to delivery.

The Limitations Are Severe

• Endotoxin contamination: Bacterial systems introduce contaminants requiring extensive purification
• Format limitations: Restricted to circular plasmid structures
• Complex sequences: Homopolymers and GC-rich regions are notoriously difficult or impossible to synthesise
• Scale constraints: Traditional methods struggle to meet growing demand

Homopolymer regions, sequences of repeated nucleotides like AAAAA, cause DNA polymerase to stall or slip, creating high error rates that lead manufacturers to reject these sequences entirely. GC-rich sequences form stable secondary structures that resist separation and cause synthesis errors. These limitations constrain what researchers can design and test.

The Next Revolution: Cell-Free Enzymatic DNA Synthesis

NunaBio has won multiple industry awards in 2025, including the Accelerating Innovation Award at CPHI Frankfurt and Innovation of the Year at the Pharma Industry Awards UK,[8] for technology that fundamentally reimagines DNA production.

Why NunaBio’s Approach Matters

Speed: Gram-scale DNA production in seven days, versus months or years with traditional methods. The NB-3 platform produces 40mg of linear DNA per 80-minute batch.

Purity: Cell-free enzymatic synthesis eliminates bacterial endotoxins and the complex purification challenges of plasmid systems, delivering DNA ready for immediate use in gene therapy and vaccine applications.

Flexibility: NunaBio’s platform produces DNA in multiple formats – short oligos, repetitive sequences, long genes, gene fragments, and homopolymers that defeat traditional synthesis methods. If others say “we can’t synthesise that sequence,” NunaBio likely can.

Scalability: The platform requires only nanograms of DNA as starting material, with a regenerative reaction process that can potentially run 24/7.

Sustainability: Enzyme-based, cell-free processes dramatically reduce environmental impact compared to bacterial fermentation, with industry projections suggesting this technology could save £583M in future costs and remove 4.4M litres of harmful phosphoramidite synthesis reagents from industrial use by 2029.[8]

Real-World Applications

NunaBio’s technology enables breakthrough applications across multiple fields:

• Gene and Cell Therapies: Rapid production of high-purity DNA vectors
• mRNA Vaccines: Fast synthesis of DNA templates for RNA manufacturing, critical for pandemic response
• Molecular Diagnostics: Custom capture probes and panels, including difficult sequences for calibrating sequencing instruments
• Synthetic Biology: Complex sequences including homopolymers for DNA origami and novel biomaterials

The Distributed Model: Coming to Australia and New Zealand

Perhaps most revolutionary is NunaBio’s distributed micro-foundry model, which allows DNA production inside a customer’s own facility. This approach transforms research sovereignty and enables rapid-response biomanufacturing, particularly critical for pandemic preparedness and regional independence.

Australia and New Zealand will be the first regions worldwide to access this capability through local research facilities in 2026.

For Australian and New Zealand researchers, this means:

• Eliminating international shipping delays
• Maintaining control over sensitive or proprietary sequences
• Enabling rapid iteration for fast-moving projects
• Building regional capacity for pandemic response
• Supporting research independence

The Continuing Evolution: What This Means for Science

From Miescher’s pus-soaked bandages in 1869 to cell-free enzymatic synthesis in 2025, the story of DNA reveals a fundamental truth about scientific progress: breakthroughs emerge from accumulated insights, persistent curiosity, and the willingness to reimagine what’s possible.

The scientists who never received Nobel recognition – Rosalind Franklin, Friedrich Miescher, Edwin Chargaff, Jerry Donohue – were absolutely essential to the story.[1,2] Their contributions made Watson and Crick’s discovery possible, just as decades of subsequent work enabled PCR[6] and modern genomics.

Today, we stand at another inflection point. Traditional DNA production models cannot meet global demand, but new technologies like NunaBio’s cell-free synthesis platform are opening possibilities that seemed impossible just years ago.

For Australian and New Zealand researchers, the arrival of distributed DNA synthesis capability in 2026 represents more than just faster timelines, it’s an opportunity to build sovereign research capacity and participate in the next wave of biotechnology innovation.

The next revolution isn’t coming – it’s already here.

Learn More

Interested in bringing cell-free DNA synthesis capability to your research facility?

ATA Scientific is proud to partner with NunaBio to bring this award-winning technology to Australia and New Zealand in 2026.

For more information about NunaBio’s NB-3 platform and distributed production options, contact ATA Scientific or visit nunabio.com.

---

About NunaBio

NunaBio is a Newcastle University spinout developing breakthrough enzymatic DNA synthesis technology. Winner of the 2025 CPHI Accelerating Innovation Award and 2025 Pharma Industry Awards Innovation of the Year, NunaBio’s cell-free platform delivers gram-scale DNA in seven days—replacing months-long bacterial production processes.

About ATA Scientific

ATA Scientific supplies cutting-edge scientific equipment and innovative technologies to research institutions and laboratories across Australia and New Zealand.

References

[1] The Nobel Prize. (2025). “The Nobel Prize in Physiology or Medicine 1962.” NobelPrize.org. Available at: https://www.nobelprize.org/prizes/medicine/1962/wilkins/facts/ [Accessed 26 November 2025]

[2] Pray, L.A. (2008). “Discovery of DNA Structure and Function: Watson and Crick.” Nature Education 1(1):100. Available at: https://www.nature.com/scitable/topicpage/discovery-of-dna-structure-and-function-watson-397/ [Accessed 26 November 2025]

[3] Dahm, R. (2007). “Discovering DNA: Friedrich Miescher and the early years of nucleic acid research.” PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/17901982/ [Accessed 26 November 2025]

[4] Wolf, G. (2003). “Friedrich Miescher, The Man Who Discovered DNA.” Bizgraphic. Available at: https://www.bizgraphic.ch/miescheriana/html/the_man_who_dicovered_dna.html [Accessed 26 November 2025]

[5] Topol, E. and Cobb, M. (2025). “The Story of Francis Crick, a new masterpiece biography by Matthew Cobb.” Ground Truths. Available at: https://open.substack.com/pub/erictopol/p/the-story-of-francis-crick-a-new [Accessed 8 December 2025]

[6] Kaunitz, J.D. (2015). “The Discovery of PCR: ProCuRement of Divine Power.” Digestive Diseases and Sciences, August 2015. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4501591/ [Accessed 28 November 2025]

[7] SynBio Technologies. (2025). “Plasmid DNA Manufacturing Guide.” Available at: https://synbio-tech.com/plasmid-dna-manufacturing-guide [Accessed 9 December 2025][8] NunaBio. (2025). “NunaBio Technology and Solutions.” Available at: https://nunabio.com/ [Accessed 9 December 2025]